Guardant Health, Inc. (GH)
| Market Cap | 13.14B |
| Revenue (ttm) | 902.57M |
| Net Income (ttm) | -398.79M |
| Shares Out | 128.84M |
| EPS (ttm) | -3.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,756,819 |
| Open | 108.84 |
| Previous Close | 108.52 |
| Day's Range | 100.68 - 108.84 |
| 52-Week Range | 29.91 - 112.43 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 79.19 (-22.38%) |
| Earnings Date | Oct 29, 2025 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p... [Read more]
Financial Performance
In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $79.19, which is a decrease of -22.38% from the latest price.
News
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple...
Senator Buys Coca-Cola, Hershey's Stock After Selling Magnificent Seven Stocks In 2025
A member of Congress who has actively been trading Magnificent Seven stocks in 2025 announced three recent stock purchases, including two food and beverage stocks ahead of the 2025 holidays.
5 Top Stocks For AI Fatigue
Turkey isn't the only thing making investors tired this Thanksgiving: AI fatigue is setting in as bubble fears rise and tech trades at dot-com era multiples. Record AI spending continues despite skept...
6 Healthcare Stocks With Strong Upward Momentum
Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of...
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 3...
Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to include late-s...
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. J...
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 21, 2025, the Compensation Committee of Guardant's...
New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps ...
Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opin...
Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million ...
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering...
Guardant Health Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of...
Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate princi...
Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts
Guardant Health, Inc.'s Shield ADLT reimbursement, Quest, and guidance raise show good adoption momentum. These positives keep me bullish on GH stock. Their oncology business remains the revenue ancho...
Why Guardant Health Was Such an Investor Darling This Week
The cancer-focused biotech surprised on the upside for both revenue and profitability in its latest reported quarter. Revenue rose by almost 40% year over year in that period.
Guardant Health: Business Continues To Gather Pace
Guardant Health delivered extremely robust Q3 results and raised full-year guidance, with Reveal and Shield beginning to make material contributions. Guardant's therapy selection and biopharma busines...
Why Guardant Health Stock Surged Today
Guardant's oncology and screening businesses are expanding at a rapid pace. New partnerships should drive further gains.
Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript
Guardant Health, Inc. ( GH) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Co-Founder, Co-CEO & Chairma...
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2...
Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights
PALO ALTO, Calif. & MCLEAN, Va.--(BUSINESS WIRE)---- $GH--Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing artificial intell...
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showi...
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented...
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market c...